10:15:48 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-15 Kvartalsrapport 2024-Q1
2024-03-27 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-12 Kvartalsrapport 2023-Q1
2023-03-24 Ordinarie utdelning CESSA 0.00 DKK
2023-03-23 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-18 Kvartalsrapport 2022-Q3
2022-11-04 Extra Bolagsstämma 2022
2022-08-19 Kvartalsrapport 2022-Q2
2022-04-19 Kvartalsrapport 2022-Q1
2022-03-18 Ordinarie utdelning CESSA 0.00 DKK
2022-03-17 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-04-19 Kvartalsrapport 2021-Q1
2021-03-29 Ordinarie utdelning CESSA 0.00 DKK
2021-03-26 Årsstämma 2021
2021-02-11 Bokslutskommuniké 2020

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriBioteknik
Cessatech är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling av smärtstillande nässpray som vidare används för behandling av akuta smärttillstånd hos barn. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och relaterade produkter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Huvudkontoret ligger i Köpenhamn.
2023-08-17 17:30:00
  • Loan facility agreement with a group of investors from Investeringsselskabet MFO Private Equity A/S, which includes some existing shareholders.  
  • Loan facility agreement for up to DKK 5 million maturing at the latest on 31 Dec 2024
  • Provides Cessatech financial flexibility and support to the planned US launch of CT001

On 17 August - Cessatech A/S ("Cessatech" or "the Company") announces that the Company has entered into a loan facility agreement with a group of investors from Investeringsselskabet MFO Private Equity A/S. The loan agreement is to support the planned US launch of CT001 and provide the company with financial flexibility against the backdrop of the current challenging capital market environment. The loan terms have been agreed upon market terms. Any amounts drawn by the Company (including accrued interest) shall rank equal with the Company's other creditors.

Jes Trygved, CEO Cessatech
"This loan facility gives us more financial flexibility during the next 18 months, as we ramp up efforts to launch CT001 in the important US market and where we expect to begin generating revenues already in 2024. Additionally, we are very pleased that the group of investors providing the loan facility includes some existing shareholders in the company, underlining their support and belief in Cessatech and our work to bring solutions to the unmet medical need of treating children who are experiencing acute pain".